Minority Based Community Clinical Oncology Program at Meharry Medical College

少数民族人口在获得适当的保健服务方面有多种障碍。这一差距特别值得注意的是， 非裔美国人的总体癌症死亡率高于所有其他种族 组此外，黑人与白色人的癌症相关死亡率之比在男性和女性中继续恶化。 女性考虑到这些事实，很明显，少数群体需要为癌症护理做出有意义的努力。 人口。这项工作的一个重点是有必要增加少数民族和服务不足的患者的应计费用， 癌症治疗（CT）和癌症预防和控制（CP/C）试验，其中少数群体是 即使是修正了他们相对于高加索人群的相对频率，他们的代表性也大大不足。这 该提案延续了梅哈里医学院MBCCOP的成功初步成果 (MMC)建立并维持了一种机制，将最先进的癌症临床试验带到少数人手中， 并让社区执业医生参与NCI申办的临床试验。本申请 将继续并加强具体目标，即：1）通过进入 大量少数民族患者进入NCI批准的CT和CP/C研究，2）涉及社区 和社区卫生中心的癌症试验，并调查其对社区医疗实践的影响， 3)增加社区执业医生对NCI批准的研究的参与，4）转移新的 向照顾少数民族和得不到充分服务的人口的卫生保健提供者提供技术。MMC，更大 超过40%的新诊断的癌症患者代表少数民族，将作为核心 由其积极的癌症研究和治疗试验计划支持。集水区将是 大都会戴维森县（MDC），少数民族人口约占整个县的33%。 人口《千年发展目标多边合作方案》的贸易和技术合作附属机构将继续包括最大的多边合作领域， 医生肿瘤学实践（萨拉坎农研究所/田纳西州肿瘤学）和唯一的少数 在纳什维尔肿瘤协会的MDC指导血液学/肿瘤学实践。这些团体一起 照顾大量的少数民族患者，并已被证明成功地将大量的 NCI批准的方案。CP/C计划将继续使用一个已建立的财团， 初级保健诊所，重点是少数民族和服务不足，以及累积到CT研究 有CP/C组件的。社区卫生中心特别适合开展CP/C 需要非癌症患者的研究，如乳腺癌预防试验。的整体设计 MBCCOP凭借其已建立的基础设施以及附属机构和明确的临床试验方法， NCI批准的CT和CP/C研究继续增加大量患者。

Minority populations have multiple impediments to proper health care. This disparity is particularly noted for cancer where African-Americans have an overall cancer death rate that is greater than for all other ethnic groups. Furthermore, the ratio of black:white cancer related mortality continues to worsen for both males and females. Considering these facts, it is clear that meaningful efforts for cancer care is required for minority populations. One focus of this effort is the necessity to increase minority and underserved patient accrual to cancer therapy (CT) and cancer prevention and control (CP/C) trials where minority populations are substantially underrepresented, even correcting for their relative frequency to Caucasian populations. This proposal continues the successful initial accomplishments of the MBCCOP at Meharry Medical College (MMC) that established and sustained a mechanism to bring state-of-the-art cancer clinical trials to minority populations and to involve community practicing physicians in NCI-sponsored clinical trials. This application will continue and enhance the specific aims that are to 1) broaden access to cancer treatment by entering substantial numbers of minority patients onto NCI approved CT and CP/C studies, 2) involve communities and community health centers in cancer trials and investigate their impact on community medical practices, 3) increase community practicing physician participation on NCI approved studies and 4) transfer new technology to health care providers caring for minority and underserved populations. MMC, with greater than 40% of newly diagnosed cancer patients representing minorities, will serve as the central core supported by its active cancer research and treatment trials program. The catchment region will be Metropolitan Davidson County (MDC) where minority populations make up approximately 33% of the entire population. The CT affiliate components of the MBCCOP will continue to include the areas largest multi- physician oncology practice (Sara Cannon Research Institute/Tennessee Oncology) and the sole minority directed hematology/oncology practice in MDC,Nashville Oncology Associates. Together, these groups care for large numbers of minority patients and have proven successful in placing substantial numbers of patients on NCI approved protocols. The CP/C program will continue to use an established consortium of primary care health clinics that focus on minorities and the underserved as well as accruing to CT studies that have CP/Ccomponents. The community health centers are particularly well-suited to performCP/C studies requiring non-cancer patients such as breast cancer prevention trials. The overall design of the MBCCOP with its established infrastructure together with affiliates and well-defined clinical trial methods will continue to accrue substantial numbers of patients onto NCI approved CT and CP/C studies.